Ensuring Quality of Life During Lung Cancer Survivorship Requires a Multidisciplinary Team

COVID-19 and Lung Cancer: A Call for Immediate Action

A Clinical Trial of PD-L1 Inhibitor Durvalumab and PARP Inhibitor Olaparib for Patients With EGFR-Mutated Transformed SCLC

Brendon Stiles, MD

Large LDCT Lung Cancer Screening Program Suggests Screening Benefits Far Outweigh the Risks

Possible Benefits of Metformin for Lung Cancer Still Unknown

Tyrosine kinase inhibitors (TKI) or monoclonal antibodies (mAb) for the Treatment of NRG1 and, Potentially, NRG2 Fusion–Positive Malignancies

Vemurafenib Alone and Combination for Lung Cancer: A Conversation with Marcelo V. Negrao, MD

Patient Advocacy Groups Fund EGFR-related Research

Mary Jo Fidler, MD

Premonitions About Lung Cancer for the Next Decade 

Pyrotinib: A Potential New Anti-HER2 Therapy for Lung Cancer